At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
olopatadine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Olopatadine Hydrochloride 0.2% Ophthalmic Solution on Epicutaneous Skin Prick Testing With Histamine and Saline
In Brief
A clinical study evaluating olopatadine and placebo for Allergic Rhinitis and Allergic Conjunctivitis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Allergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
Primary CompletionJun 2008
First PostedOct 2008
TodayJul 2026
First PostedOct 20, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.7 years ago
Interventions
olopatadinedrug
olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
placebodrug
placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day